Prometheus Laboratories

Pharma

Even after Prometheus, Acceleron deals, Merck primed for M&A

Even after the acquisitions of Prometheus and Acceleron, Merck is ready to make more deals in the $1 to $15 billion range, according to CEO Rob Davis.

Kevin Dunleavy Feb 1, 2024 11:01am

After recent moves, Merck no longer focused on Keytruda deadline

Apr 27, 2023 1:22pm